journal
MENU ▼
Read by QxMD icon Read
search

European Journal of Heart Failure

journal
https://www.readbyqxmd.com/read/28516737/iron-status-and-inflammatory-biomarkers-in-patients-with-acutely-decompensated-heart-failure-early-in-hospital-phase-and-30-day-follow-up
#1
Lucas N L Van Aelst, Marjorie Abraham, Malha Sadoune, Thibaud Lefebvre, Philippe Manivet, Damien Logeart, Jean-Marie Launay, Zoubida Karim, Hervé Puy, Alain Cohen-Solal
No abstract text is available yet for this article.
May 17, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28516519/exercise-training-in-diastolic-heart-failure-ex-dhf-rationale-and-design-of-a-multicentre-prospective-randomized-controlled-parallel-group-trial
#2
Frank Edelmann, Anna Bobenko, Götz Gelbrich, Gerd Hasenfuss, Christoph Herrmann-Lingen, André Duvinage, Silja Schwarz, Meinhard Mende, Christiane Prettin, Tobias Trippel, Ruhdja Lindhorst, Daniel Morris, Elisabeth Pieske-Kraigher, Kathleen Nolte, Hans-Dirk Düngen, Rolf Wachter, Martin Halle, Burkert Pieske
Heart failure with preserved ejection fraction (HFpEF) is a common disease with high incidence and increasing prevalence. Patients suffer from functional limitation, poor health-related quality of life, and reduced prognosis. A pilot study in a smaller group of HFpEF patients showed that structured, supervised exercise training (ET) improves maximal exercise capacity, diastolic function, and physical quality of life. However, the long-term effects of ET on patient-related outcomes remain unclear in HFpEF. The primary objective of the Exercise training in Diastolic Heart Failure (Ex-DHF) trial is to investigate whether a 12 month supervised ET can improve a clinically meaningful composite outcome score in HFpEF patients...
May 17, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28516504/prognostic-potential-of-midregional-pro-adrenomedullin-following-decompensation-for-systolic-heart-failure-comparison-with-cardiac-natriuretic-peptides
#3
Caroline Morbach, Almuth Marx, Mathias Kaspar, Gülmisal Güder, Susanne Brenner, Carolin Feldmann, Stefan Störk, Jörn O Vollert, Georg Ertl, Christiane E Angermann
AIMS: Whereas guidelines recommend the routine use of natriuretic peptides (NPs) in heart failure (HF) care, the clinical relevance and prognostic potential of midregional pro-adrenomedullin (MR-proADM) is less well established. We aimed to compare the prognostic potential of MR-proADM after acute decompensation for systolic HF with that of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and midregional pro-atrial NP (MR-proANP), to investigate the significance of high/rising MR-proADM, and to evaluate the incremental prognostic yield of repeat measurements...
May 17, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28493370/guided-left-ventricular-lead-placement-for-cardiac-resynchronization-therapy-an-opportunity-for-image-integration-reply
#4
LETTER
Anders Sommer, Mads B Kronborg, Jens C Nielsen
No abstract text is available yet for this article.
May 11, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28474436/are-circulating-relaxin-levels-related-to-pulmonary-hypertension-in-patients-with-heart-failure-a-reply
#5
LETTER
Mariana Pintalhao, Paulo Castro-Chaves, Paulo Bettencourt
No abstract text is available yet for this article.
May 4, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28470962/do-patients-have-worse-outcomes-in-heart-failure-than-in-cancer-a-primary-care-based-cohort-study-with-10-year-follow-up-in-scotland
#6
Mamas A Mamas, Matthew Sperrin, Margaret C Watson, Alasdair Coutts, Katie Wilde, Christopher Burton, Umesh T Kadam, Chun Shing Kwok, Allan B Clark, Peter Murchie, Iain Buchan, Philip C Hannaford, Phyo K Myint
AIMS: This study was designed to evaluate whether survival rates in patients with heart failure (HF) are better than those in patients with diagnoses of the four most common cancers in men and women, respectively, in a contemporary primary care cohort in the community in Scotland. METHODS AND RESULTS: Data were obtained from the Primary Care Clinical Informatics Unit from a database of 1.75 million people registered with 393 general practices in Scotland. Sex-specific survival modelling was undertaken using Cox proportional hazards models, adjusted for potential confounders...
May 3, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28464427/pulmonary-hypertension-due-to-left-heart-disease-analysis-of-survival-according-to-the-haemodynamic-classification-of-the-2015-esc-ers-guidelines-and-insights-for-future-changes
#7
Massimiliano Palazzini, Fabio Dardi, Alessandra Manes, Maria L Bacchi Reggiani, Enrico Gotti, Andrea Rinaldi, Alessandra Albini, Enrico Monti, Nazzareno Galiè
AIMS: Pulmonary hypertension (PH) is a relevant complication of left heart disease (LHD). The 2015 ESC/ERS PH guidelines report two different haemodynamic subsets of PH due to LHD (PH-LHD) based on levels of pulmonary vascular resistance (PVR) and diastolic pressure gradient (DPG): isolated post-capillary PH (Ipc-PH) and combined post- and pre-capillary PH (Cpc-PH). The objective of this study is to evaluate the prognostic value of Ipc-PH and Cpc-PH. METHODS AND RESULTS: Data from 276 consecutive incident patients with PH-LHD were included...
May 2, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28464398/finding-the-road-to-recovery-therapeutic-and-clinical-trial-implications-of-dysfunctional-viable-myocardium-in-heart-failure-with-reduced-ejection-fraction
#8
EDITORIAL
Stephen J Greene, Muthiah Vaduganathan, Mihai Gheorghiade
No abstract text is available yet for this article.
May 2, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28463464/physicians-guideline-adherence-is-associated-with-better-prognosis-in-outpatients-with-heart-failure-with-reduced-ejection-fraction-the-qualify-international-registry
#9
Michel Komajda, Martin R Cowie, Luigi Tavazzi, Piotr Ponikowski, Stefan D Anker, Gerasimos S Filippatos
AIMS: To evaluate the impact of physicians' adherence to guideline-recommended medications for heart failure with reduced ejection fraction (HFrEF), including ≥50% prescription of recommended doses, on clinical outcomes at 6-month follow-up. METHODS AND RESULTS: In QUALIFY, an international, prospective, observational, longitudinal survey, 6669 outpatients with HFrEF were recruited 1-15 months after heart failure (HF) hospitalization from September 2013 to December 2014 in 36 countries and followed up at 6 months...
April 30, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28463462/clinical-phenotypes-and-outcome-of-patients-hospitalized-for-acute-heart-failure-the-esc-heart-failure-long-term-registry
#10
Ovidiu Chioncel, Alexandre Mebazaa, Veli-Pekka Harjola, Andrew J Coats, Massimo Francesco Piepoli, Maria G Crespo-Leiro, Cecile Laroche, Petar M Seferovic, Stefan D Anker, Roberto Ferrari, Frank Ruschitzka, Silvia Lopez Fernandez, Daniela Miani, Gerasimos Filippatos, Aldo P Maggioni
AIMS: To identify differences in clinical epidemiology, in-hospital management and 1-year outcomes among patients hospitalized for acute heart failure (AHF) and enrolled in the European Society of Cardiology Heart Failure Long-Term (ESC-HF-LT) Registry, stratified by clinical profile at admission. METHODS AND RESULTS: The ESC-HF-LT Registry is a prospective, observational study collecting hospitalization and 1-year follow-up data from 6629 AHF patients. Among AHF patients enrolled in the registry, 13...
April 30, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28462519/effect-of-ivabradine-in-patients-with-heart-failure-with-preserved-ejection-fraction-the-edify-randomized-placebo-controlled-trial
#11
Michel Komajda, Richard Isnard, Alain Cohen-Solal, Marco Metra, Burkert Pieske, Piotr Ponikowski, Adriaan A Voors, Fabienne Dominjon, Cécile Henon-Goburdhun, Matthieu Pannaux, Michael Böhm
AIMS: This randomized, double-blind, placebo-controlled trial assessed whether heart rate (HR) reduction with ivabradine improves cardiac function in heart failure with preserved ejection fraction (HFpEF). METHODS AND RESULTS: The prEserveD left ventricular ejectIon fraction chronic heart Failure with ivabradine studY (EDIFY) included 179 patients in New York Heart Association (NYHA) classes II and III, in sinus rhythm, with HR of ≥70 b.p.m., NT-proBNP of ≥220 pg/mL (BNP ≥80 pg/mL) and left ventricular ejection fraction of ≥45%...
April 30, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28452195/serelaxin-in-addition-to-standard-therapy-in-acute-heart-failure-rationale-and-design-of-the-relax-ahf-2-study
#12
John R Teerlink, Adriaan A Voors, Piotr Ponikowski, Peter S Pang, Barry H Greenberg, Gerasimos Filippatos, G Michael Felker, Beth A Davison, Gad Cotter, Claudio Gimpelewicz, Leandro Boer-Martins, Margaret Wernsing, Tsushung A Hua, Thomas Severin, Marco Metra
Patients admitted for acute heart failure (AHF) experience high rates of in-hospital and post-discharge morbidity and mortality despite current therapies. Serelaxin is recombinant human relaxin-2, a hormone with vasodilatory and end-organ protective effects believed to play a central role in the cardiovascular and renal adaptations of human pregnancy. In the phase 3 RELAX-AHF trial, serelaxin met its primary endpoint of improving dyspnoea through day 5 in patients admitted for AHF. Compared to placebo, serelaxin also reduced worsening heart failure (WHF) by 47% through day 5 and both all-cause and cardiovascular mortality by 37% through day 180...
April 28, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28436136/effects-of-ferric-carboxymaltose-on-hospitalisations-and-mortality-rates-in-iron-deficient-heart-failure-patients-an-individual-patient-data-meta-analysis
#13
Stefan D Anker, Bridget-Anne Kirwan, Dirk J van Veldhuisen, Gerasimos Filippatos, Josep Comin-Colet, Frank Ruschitzka, Thomas F Lüscher, Gregory P Arutyunov, Michael Motro, Claudio Mori, Bernard Roubert, Stuart J Pocock, Piotr Ponikowski
AIMS: Iron deficiency (ID) is a common co-morbidity in patients with heart failure (HF) and has been suggested to be associated with poor prognosis. Recently completed double-blind randomised controlled trials (RCTs) studying HF patients with ID have shown improvements in functional capacity, symptoms and quality of life when treated with i.v. ferric carboxymaltose (FCM). This individual patient data meta-analysis investigates the effect of FCM vs. placebo on recurrent hospitalisations and mortality in HF patients with ID...
April 24, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28425168/right-ventricular-failure-after-left-ventricular-assist-device-implant-towards-finding-common-ground
#14
EDITORIAL
Jorge Silva Enciso, Barry Greenberg
No abstract text is available yet for this article.
April 19, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28425164/the-fallacy-of-resting-echocardiographic-parameters-of-cardiac-function-in-heart-failure-with-preserved-ejection-fraction-add-global-longitudinal-strain-to-the-list
#15
EDITORIAL
Dragoş Vinereanu, Andrei D Mǎrgulescu
No abstract text is available yet for this article.
April 19, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28401618/tailoring-mineralocorticoid-receptor-antagonist-therapy-in-heart-failure-patients-are-we-moving-towards-a-personalized-approach
#16
REVIEW
João Pedro Ferreira, Robert J Mentz, Anne Pizard, Bertram Pitt, Faiez Zannad
The aim of personalized medicine is to offer a tailored approach to each patient in order to provide the most effective therapy, while reducing risks and side effects. The use of mineralocorticoid receptor antagonists (MRAs) has demonstrated major benefits in heart failure with reduced ejection fraction (HFrEF), results with challenging inconsistencies in heart failure with preserved ejection fraction (HFpEF), and 'neutral' preliminary results in acute heart failure. Data derived from landmark trials are generally applied in a 'one size fits all' manner and the development and implementation of more personalized MRA management would offer the potential to improve outcomes and reduce side effects...
April 12, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28393439/effect-of-intracoronary-administration-of-aav1-serca2a-on-ventricular-remodelling-in-patients-with-advanced-systolic-heart-failure-results-from-the-agent-hf-randomized-phase-2-trial
#17
Jean-Sébastien Hulot, Joe-Elie Salem, Alban Redheuil, Jean-Philippe Collet, Shaida Varnous, Patrick Jourdain, Damien Logeart, Estelle Gandjbakhch, Claude Bernard, Stéphane N Hatem, Richard Isnard, Philippe Cluzel, Claude Le Feuvre, Pascal Leprince, Nadjib Hammoudi, François M Lemoine, David Klatzmann, Eric Vicaut, Michel Komajda, Gilles Montalescot, Anne-Marie Lompré, Roger J Hajjar
AIMS: Restoration of sarco/endoplasmic reticulum Ca(2+) ATPase (SERCA2a) activity through gene transfer improved cardiac function in experimental and pilot studies in humans with heart failure. The AGENT-HF (NCT01966887) trial investigated the impact of adeno-associated virus (AAV1)/SERCA2a on ventricular remodelling using multimodality non-invasive cardiac imaging. METHODS AND RESULTS: AGENT-HF was a single centre, randomized, double-blind, placebo-controlled trial in adult patients with NYHA class III-IV ischaemic or non-ischaemic heart failure and left ventricular ejection fraction ≤35%...
April 10, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28387033/non-invasive-measurement-of-right-atrial-pressure-by-near-infrared-spectroscopy-preliminary-experience-a-report-from-the-sica-hf-study
#18
Pierpaolo Pellicori, Andrew L Clark, Anna Kallvikbacka-Bennett, Jufen Zhang, Alessia Urbinati, Luca Monzo, Riet Dierckx, Stefan D Anker, John G F Cleland
AIMS: To assess the clinical value of measuring right atrial pressure (RAP) using near-infrared spectroscopy (NIRS) in patients with chronic heart failure (CHF). METHODS AND RESULTS: RAP was measured non-invasively using NIRS over the external jugular vein (Venus 1000, Mespere LifeSciences, Canada) in ambulatory patients with CHF enrolled in the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF) programme. Comparing 243 patients with CHF (mean age 71 years; mean left ventricular ejection fraction (LVEF) 45%, median NT-proBNP 788 ng/L) to 49 controls (NT-proBNP ≤125 ng/L), RAP was 7 [interquartile range (IQR) 4-11] mmHg vs...
April 6, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28387002/recovered-heart-failure-with-reduced-ejection-fraction-and-outcomes-a-prospective-study
#19
Josep Lupón, Carles Díez-López, Marta de Antonio, Mar Domingo, Elisabet Zamora, Pedro Moliner, Beatriz González, Javier Santesmases, Maria I Troya, Antoni Bayes-Genis
AIMS: Significant recovery of left ventricular ejection fraction (LVEF) occurs in a proportion of patients with heart failure (HF) and reduced ejection fraction (HFrEF). We analysed outcomes, including mortality [all-cause, cardiovascular (CV), HF-related, and sudden death], and HF-related hospitalizations in this HF-recovered group. The primary endpoint was a composite of CV death or HF hospitalization. METHODS AND RESULTS: LVEF was assessed at baseline and at 1 year in 1057 consecutive HF patients...
April 6, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28386917/epidemiology-and-one-year-outcomes-in-patients-with-chronic-heart-failure-and-preserved-mid-range-and-reduced-ejection-fraction-an-analysis-of-the-esc-heart-failure-long-term-registry
#20
Ovidiu Chioncel, Mitja Lainscak, Petar M Seferovic, Stefan D Anker, Maria G Crespo-Leiro, Veli-Pekka Harjola, John Parissis, Cecile Laroche, Massimo Francesco Piepoli, Candida Fonseca, Alexandre Mebazaa, Lars Lund, Giuseppe A Ambrosio, Andrew J Coats, Roberto Ferrari, Frank Ruschitzka, Aldo P Maggioni, Gerasimos Filippatos
AIMS: The objectives of the present study were to describe epidemiology and outcomes in ambulatory heart failure (HF) patients stratified by left ventricular ejection fraction (LVEF) and to identify predictors for mortality at 1 year in each group. METHODS AND RESULTS: The European Society of Cardiology Heart Failure Long-Term Registry is a prospective, observational study collecting epidemiological information and 1-year follow-up data in 9134 HF patients. Patients were classified according to baseline LVEF into HF with reduced EF [EF <40% (HFrEF)], mid-range EF [EF 40-50% (HFmrEF)] and preserved EF [EF >50% (HFpEF)]...
April 6, 2017: European Journal of Heart Failure
journal
journal
34664
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"